Saturday, November 07, 2020 12:25:47 AM
According to my CEO friend in the bio pharma industry, they could also have told you a fib. He has never heard of a placeholder abstract, as conferences would never accept such a thing. The abstract submitted have to be certain enough for them to accept it. If they didn't have demands for the level of abstract submitted, every bio pharma company would submit to every conference, just in case.
They might have meant it as a placeholder, but they probably had to submit enough of an abstract to get admitted to the conference. These conferences have deadline to withdraw, and in the case of SITC, it was Oct. 15.
Please don't misunderstand me, but DI can pretty much tell you anything in a phone call without any legal consequence.
I am sure you are right and this is what has actually transpired, but I wouldn't be surprised to see a different tone Monday morning. It doesn't really matter as the market is currently closed and if SITC does publish whatever they submitted, Company would know it in time to send out a PR Monday morning.
I will only post what I have been told by those with experience in this industry. I will not engage in speculations without clearly stating that it is just my opinion. I think anything else is irresponsible.
GLTA and patients.
They might have meant it as a placeholder, but they probably had to submit enough of an abstract to get admitted to the conference. These conferences have deadline to withdraw, and in the case of SITC, it was Oct. 15.
Please don't misunderstand me, but DI can pretty much tell you anything in a phone call without any legal consequence.
I am sure you are right and this is what has actually transpired, but I wouldn't be surprised to see a different tone Monday morning. It doesn't really matter as the market is currently closed and if SITC does publish whatever they submitted, Company would know it in time to send out a PR Monday morning.
I will only post what I have been told by those with experience in this industry. I will not engage in speculations without clearly stating that it is just my opinion. I think anything else is irresponsible.
GLTA and patients.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
